
NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks
Publication
, Conference
Harrison, S; Rossi, S; Bashir, M; Guy, C; Banerjee, R; Jaros, M; Owers, S; Baxter, B; Ling, L; Depaoli, A
Published in: Journal of Hepatology
April 2018
Duke Scholars
Published In
Journal of Hepatology
DOI
ISSN
0168-8278
Publication Date
April 2018
Volume
68
Start / End Page
S65 / S66
Publisher
Elsevier BV
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, S., Rossi, S., Bashir, M., Guy, C., Banerjee, R., Jaros, M., … Depaoli, A. (2018). NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks. In Journal of Hepatology (Vol. 68, pp. S65–S66). Elsevier BV. https://doi.org/10.1016/s0168-8278(18)30352-0
Harrison, S., S. Rossi, M. Bashir, C. Guy, R. Banerjee, M. Jaros, S. Owers, B. Baxter, L. Ling, and A. Depaoli. “NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks.” In Journal of Hepatology, 68:S65–66. Elsevier BV, 2018. https://doi.org/10.1016/s0168-8278(18)30352-0.
Harrison S, Rossi S, Bashir M, Guy C, Banerjee R, Jaros M, et al. NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks. In: Journal of Hepatology. Elsevier BV; 2018. p. S65–6.
Harrison, S., et al. “NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks.” Journal of Hepatology, vol. 68, Elsevier BV, 2018, pp. S65–66. Crossref, doi:10.1016/s0168-8278(18)30352-0.
Harrison S, Rossi S, Bashir M, Guy C, Banerjee R, Jaros M, Owers S, Baxter B, Ling L, Depaoli A. NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks. Journal of Hepatology. Elsevier BV; 2018. p. S65–S66.

Published In
Journal of Hepatology
DOI
ISSN
0168-8278
Publication Date
April 2018
Volume
68
Start / End Page
S65 / S66
Publisher
Elsevier BV
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences